Literature DB >> 18535750

Knockdown of STAT3 by shRNA inhibits the growth of CAOV3 ovarian cancer cell line in vitro and in vivo.

Feng Huang1, Xiaoyun Tong, Liangqing Fu, Ronghua Zhang.   

Abstract

Constitutively activated signal transducer and activator of transcription 3 (STAT3) plays an important role in the formation of many tumors including ovarian cancer. In this study, RNA interference specific to STAT3 was employed to study its effects on the inhibition of STAT3 signaling and on the growth of ovarian cancer CAOV3 cells. Plasmid vectors pGenesil-1-GFP-U6 expressing specific small hairpin RNA (shRNA) against STAT3 and the scrambled shRNA control were constructed. After transfection into CAOV3 cells, the STAT3 shRNA specifically suppressed STAT3 expression at both mRNA and protein levels. At the same time, expressions of Bcl-xL, cyclin D1, and c-myc were down-regulated, whereas the cleaved caspase 3 was up-regulated. In addition, STAT3 knockdown inhibited anchorage-independent growth and induced apoptosis in CAOV3 cells, and decreased tumor growth in nude mice implanted with ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18535750     DOI: 10.1111/j.1745-7270.2008.00424.x

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  10 in total

1.  Role of human herpesvirus 8 interleukin-6-activated gp130 signal transducer in primary effusion lymphoma cell growth and viability.

Authors:  Emily Cousins; John Nicholas
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

2.  Activation of the IL-6/JAK/STAT3 signaling pathway in human middle ear cholesteatoma epithelium.

Authors:  Wei Liu; Shumin Xie; Xing Chen; Xingwang Rao; Hongmiao Ren; Bing Hu; Tuanfang Yin; Yuyan Xiang; Jihao Ren
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

3.  Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target.

Authors:  Uksha Saini; Shan Naidu; Adam C ElNaggar; Hemant Kumar Bid; John J Wallbillich; Kristin Bixel; Chelsea Bolyard; Adrian A Suarez; Balveen Kaur; Periannan Kuppusamy; John Hays; Paul J Goodfellow; David E Cohn; Karuppaiyah Selvendiran
Journal:  Oncogene       Date:  2016-06-13       Impact factor: 9.867

4.  Knockdown of stat3 expression by RNAi inhibits in vitro growth of human ovarian cancer.

Authors:  Shu-Hua Zhao; Fan Zhao; Jing-Ying Zheng; Li-Fang Gao; Xue-Jian Zhao; Man-Hua Cui
Journal:  Radiol Oncol       Date:  2011-04-28       Impact factor: 2.991

5.  STAT3 Knockdown Induces Tumor Formation by MDA-MB-231 Cells.

Authors:  Kasturi Banerjee; Cindy Pru; James K Pru; Haluk Resat
Journal:  Clin Oncol Res       Date:  2018-03-26

6.  Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.

Authors:  Hongyi Li; Yanping Qian; Xi Wang; Ruyu Pi; Xia Zhao; Xiawei Wei
Journal:  Cell Prolif       Date:  2019-11-28       Impact factor: 6.831

7.  Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.

Authors:  Sun-Ae Park; Lee Kyung Kim; Hye Min Park; Hee Jung Kim; Tae-Hwe Heo
Journal:  Oncol Rep       Date:  2022-01-14       Impact factor: 3.906

8.  Preclinical therapeutic potential of a nitrosylating agent in the treatment of ovarian cancer.

Authors:  Shailendra Giri; Ramandeep Rattan; Mandar Deshpande; Jacie L Maguire; Zachary Johnson; Rondell P Graham; Viji Shridhar
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

Review 9.  STAT3 signaling in ovarian cancer: a potential therapeutic target.

Authors:  Renba Liang; Xishan Chen; Li Chen; Fangzhu Wan; Kaihua Chen; Yongchu Sun; Xiaodong Zhu
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

10.  MicroRNA-411 Inhibits Cervical Cancer Progression by Directly Targeting STAT3.

Authors:  Dan Shan; Yumin Shang; Tongxiu Hu
Journal:  Oncol Res       Date:  2018-05-01       Impact factor: 5.574

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.